Predictive Role of O6-Methylguanine DNA Methyltransferase Status for the Treatment of Brain Tumors

摘要: Alkylating cytotoxic agents remain a backbone for the systemic therapy of brain tumors. However, efficacy temozolomide or other drugs this class varies dramatically between patients, being negligible in some cases but critical disease outcome others. Search predictive markers led to discovery role O 6-methylguanine DNA methyltransferase (MGMT), an enzyme involved removal alkyl groups N7 and O6 positions guanine. Low expression MGMT has been repeatedly shown be associated with pronounced tumor sensitivity treatment. Nevertheless, methodological issues status determination subject investigation. Furthermore, while grade IV malignant gliomas (glioblastomas) have analyzed sufficient level comprehension, there are just few studies dedicated less aggressive varieties CNS malignancies. This chapter presents update on clinical status.